 |
|
Intrathecal Aminopterin Therapy of Meningeal Leukemia
RICHARD E. RIESELBACH, M.D.;
EDWARD E. MORSE, M.D.;
DAVID P. RALL, M.D., Ph.D.;
EMIL FREI III, M.D.;
EMIL J. FREIREICH, M.D.
Arch Intern Med. 1963;111(5):620-630.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
Meningeal leukemia is an important complication of acute leukemia.3 While chemotherapy has resulted in prolongation of survival,4 the effective antimetabolites do not reach therapeutic levels in the cerebrospinal fluid.5,6 As a result, meningeal leukemia has become the major therapeutic problem in patients with acute leukemia in remission, as well as being a serious complication encountered in patients with active leukemia.3
Intrathecal methotrexate (Amethopterin) has been used for the treatment of meningeal leukemia.7-9 At dosages usually employed, this therapy has often been adequate to control symptoms. However, in cases which do not respond, further increments in dosage have been limited by concern regarding neurotoxicity. Wollner et al. described seizures in dogs following 1.0-1.5 mg. per kilogram of methotrexate administered by cisternal injection.10 Moreover, neurotoxicity of folic acid antagonists related to the quantity of pteroylglutamic acid, not to the antifolic activity of the compound.10 Therefore,
. . . [Full Text PDF of this Article]
Author Affiliations
BETHESDA, MD.
From the Medicine Branch, National Cancer Institute, National Institutes of Health.
Footnotes
Received for publication Aug. 9, 1962; accepted Oct. 16.
Preliminary accounts of this work have been previously published.1,2
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
